RPS6KB1 and neoplasm: Given the obvious advantages of directly inhibiting S6K1 phosphorylation, we examined p-S6K1 as a target in tumors exhibiting intrinsic or acquired resistance and in models portraying tumor plasticity- neuroendocrine differentiation and heterogeneity exemplified in PRISM analysis of diverse cancer cell lines.